Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Funder
- European Commission · Horizon Europe
- Award amount
- €9,000,000 – €11,000,000
- Deadline
- February 17, 2027
- Eligible countries
- European Union, United Kingdom, Norway, Iceland, Switzerland, Israel, Global
Summary
Forthcoming EU call topic HORIZON-HLTH-2027-01-DISEASE-05 · HORIZON Research and Innovation Actions. Part of call HORIZON-HLTH-2027-01: Cluster 1 - Health (Single stage - 2027/1). Opens 2026-10-29; next deadline 2027-02-17. Topic page: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2027-01-DISEASE-05
Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: - The scientific and clinical communities have a better understanding of and access to experimental antivirals for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. - Candidate antiviral therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.
Scope: Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of antivirals targeting conserved viral or host mechanisms would provide a critical preparedness measure against future health threats caused by (re)emerging infectious disease epidemics or pandemics, due to infectious disease epidemics or pandemics. This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation of the European Medical Countermeasures Strategy[1]. Antibodies and antibody derived proteins are excluded…
Summary as listed by the funder. Always read the full announcement for eligibility, limits and how to apply.
Read the full announcement →What European Union reviewers look for
- Most Horizon Europe calls score three criteria (the ERC uses excellence alone). Excellence: clarity and ambition of the objectives, and the soundness of the methodology.
- Impact: credible pathways to the expected outcomes, and measures to communicate and exploit results.
- Quality and efficiency of implementation: the work plan, resources and the consortium's capacity.
Read our guide: what funded applications do →
See how this call matches your research
Build a free research profile and Lantern Grants scores every open call against your work, tracks your deadlines and reminds you before they pass.
Get matched free